# Renato D. Lópes

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/renato-d-lopes/

## Facts

| Field | Value |
| --- | --- |
| Citations | 67,044 |
| Field | Atrial Fibrillation Management and Outcomes |
| h-index | 117 |
| i10-index | 545 |
| Last Known Institution | Alnylam Pharmaceuticals (United States) |
| OpenAlex ID | https://openalex.org/A5067237537 |
| ORCID iD | 0000-0003-2999-4961 |
| Works | 1,240 |

## Researcher papers

Showing 12 of 21.

- [Apixaban versus Warfarin in Patients with Atrial Fibrillation](https://scholariq.org/papers/apixaban-versus-warfarin-in-patients-with-atrial-fibrillation/)
- [Initial Invasive or Conservative Strategy for Stable Coronary Disease](https://scholariq.org/papers/initial-invasive-or-conservative-strategy-for-stable-coronary-disease/)
- [Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure](https://scholariq.org/papers/sotagliflozin-in-patients-with-diabetes-and-recent-worsening-heart-failure/)
- [Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial](https://scholariq.org/papers/albiglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes-and/)
- [Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials](https://scholariq.org/papers/cardiovascular-mortality-and-kidney-outcomes-with-glp-1-receptor-agonists-in-2/)
- [Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/effect-of-interleukin-1-inhibition-with-canakinumab-on-incident-lung-cancer-in/)
- [Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19](https://scholariq.org/papers/effect-of-dexamethasone-on-days-alive-and-ventilator-free-in-patients-with/)
- [Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation](https://scholariq.org/papers/antithrombotic-therapy-after-acute-coronary-syndrome-or-pci-in-atrial/)
- [Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease](https://scholariq.org/papers/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-disease/)
- [Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19](https://scholariq.org/papers/hydroxychloroquine-with-or-without-azithromycin-in-mild-to-moderate-covid-19/)
- [Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome](https://scholariq.org/papers/apixaban-with-antiplatelet-therapy-after-acute-coronary-syndrome/)
- [Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial](https://scholariq.org/papers/efficacy-of-apixaban-when-compared-with-warfarin-in-relation-to-renal-function/)

## Researcher topics

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Acute Myocardial Infarction Research](https://scholariq.org/topics/acute-myocardial-infarction-research/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)
- [Coronary Interventions and Diagnostics](https://scholariq.org/topics/coronary-interventions-and-diagnostics/)

## Researcher university

- [Alnylam Pharmaceuticals (United States)](https://scholariq.org/institutions/alnylam-pharmaceuticals-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.